A clinical trial of the world's first mRNA lung cancer vaccine has been started in the UK. Experts stated it as a revolutionary advancement in the treatment of lung cancer.

A 67-year-old UK resident has become the first person to take this vaccine.

The phase 1 clinical trial has commenced at 34 research sites across seven countries: the UK, the US, Germany, Hungary, Poland, Spain, and Turkey.

Additionally, University College London Hospitals NHS Foundation Trust in the UK will conduct a trial with 130 patients with various health conditions, including those with pre-surgery or radiotherapy, those in late-stage cancer, or those experiencing recurrence.

The vaccine, known as BNT116 and produced by BioNTech, is designed to treat non-small cell lung cancer, the most prevalent form of the disease. This vaccine is designed to selectively destroy cancer cells while minimizing impact on healthy cells and reducing side effects. 

Lung cancer is the most fatal cancer worldwide, claiming more lives than any other form of the disease. Lung cancer is more prevalent among older people, and the average age of affected people is 75 years. It is very rare in people aged below 40 years.

The major cause of lung cancer is smoking. Reject smoking and steer clear of passive smoking to protect your health. Active smokers face a 23-fold higher risk of developing lung cancer, while passive smokers are at a 13-fold increased risk.

It’s high time we should turn the tide against this cancer. Promoting social awareness and taking small steps can help reduce the chances of developing lung cancer.